HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account

Clinical Trial


Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

          In this trial, we aim to improve the outcomes of haplo cord transplant. Haplo cord transplant is a novel and promising way to improve transplant outcomes. We hypothesize that identification of a graft that is at least 5/6 matched and inherited paternal antigen (IPA) targeted (i.e., cord blood grafts share one or more IPA antigens with the prospective recipient) is more important to the outcome of haplo cord transplant than the nucleated cell dose. The identification of such a graft for a large proportion of the subjects may necessitate accepting a lower umbilical cord graft dose.

In addition to a umbilical cord blood transplant, recipients will receive stem cells from a family member ( a haplo-identical donor) . After collection and prior to infusion, these cells will be purified using a device called a CliniMACS CD34 selection device. The subject will undergo a chemotherapy conditioning regimen prior to transplantation. No experimental drugs are used in this study, and the combinations of drugs that will be used in the conditioning regimen are combinations that have been used in the past.

Est. Enrollment: 500 participants

The number of participants in a clinical study. The "estimated" enrollment is the target number of participants the researchers need for the study.

Study Start Date: Oct 16, 2012

These are the dates the researchers think the study will start and end.

Study Completion Date: Dec 01, 2025

The "estimated" study completion date is the date the researchers think the last participant in a clinical study was examined or received an intervention/treatment. This is also the expected date that the study will be completed

Age: 18+ years

Gender: All

Who can join expand_less
  • Subject must have a confirmed diagnosis of:
  • Previously Relapsed or refractory acute leukemia (myeloid or lymphoid)
  • Acute leukemia in first remission at high-risk for recurrence
  • Chronic myelogenous leukemia in chronic, accelerated phase or blast-crisis
  • Recurrent or refractory malignant lymphoma or Hodgkin lymphoma
  • Chronic lymphocytic leukemia, relapsed or with poor prognostic features
  • Multiple myeloma
  • Myelodysplastic syndrome
  • Chronic myeloproliferative disease
  • Hemoglobinopathies
  • Aplastic anemia
  • Other hematological disorder in need of allogeneic transplant (e.g. blastoid dendritic cell neoplasm)
  • Age ≥ 18 years
  • Likely to benefit from allogeneic transplant in the opinion of the transplant physician
  • An HLA-identical related or unrelated donor cannot be identified within an appropriate time frame.
  • Karnofsky (KPS) Performance status of >= 70%
  • Acceptable organ function as defined below: Serum bilirubin: < 2.0mg/dL ALT(SGPT): < 3 X upper limit of normal Creatinine Clearance: > 50 mL/min/1.73m2 (as estimated by the modified MDRD equation)
  • Ability to understand and the willingness to sign a written informed consent document
Who cannot join expand_less
  • Life expectancy is severely limited by concomitant illness or uncontrolled infection
  • Severely decreased Left Ventricular Ejection Fraction (LVEF) or impaired pulmonary function tests (PFT's)
  • Evidence of chronic active hepatitis or cirrhosis
  • Uncontrolled HIV disease
  • Pregnant or lactating
Study Description expand_more
Study Details expand_more

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube